The critical parameters in GH excess

Journal of Endocrinological Investigation

Volumn 28, Issue 5 SUPPL, 2005, Pages 92-95

  Sheppard, M C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acromegaly mortality monitoring; GH; Insulin like growth factor I (IGF I)

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; GROWTH HORMONE; HORMONE ANTAGONIST; SOMATOMEDIN C; SOMATOSTATIN; HUMAN GROWTH HORMONE;

ACROMEGALY; CONFERENCE PAPER; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; LIFE EXPECTANCY; MORBIDITY; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; RECURRENT DISEASE; RISK ASSESSMENT; SURVIVAL; SURVIVOR; TREATMENT RESPONSE; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ACROMEGALY; HUMAN GROWTH HORMONE; HUMANS;

EID: 27744576293     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 387-99.
2. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613-7.
3. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293-9.
4. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994, 41: 95-102.
5. Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
6. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
7. Trainer PJ. Editorial: Acromegaly-consensus, what consensus? J Clin Endocrinol Metab 2002, 87: 3534-6.
8. Ayuk J, Sheppard MC. The role of growth hormone-receptor antagonism in relation to acromegaly. Expert Opin Pharmacother 2004, 5: 1-7.
9. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667-74.
10. Holdaway IM, Rajasoorya RC, Gamble GD. Evidence for the use of IGF-I as a predictor of mortality in acromegaly is lacking. J Clin Endocrinol Metab 2004, 89: 5868.
11. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003, 58: 86-92.
12. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor-I measurements. J Clin Endocrinol Metab 2004, 89: 2789-96.
13. Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol(Oxf) 1995, 42: 417-23.
14. Kaltsas GA, Isidori AM, Florakis D, et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing post-operative disease activity. J Clin Endocrinol Metab 2001, 86: 1645-52.
15. Abosch A, Tyrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998, 83: 3411-8.
16. Freda PU, Nuruzzaman AT, Reyes CM, Sunden RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004, 89: 495-500.